Zoetis Inc. (NYSE:ZTS) Receives $211.75 Average PT from Brokerages

Zoetis Inc. (NYSE:ZTS) has earned an average rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $211.75.

A number of analysts recently weighed in on ZTS shares. The Goldman Sachs Group decreased their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research note on Monday, May 6th. Stifel Nicolaus lowered their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. HSBC reduced their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Piper Sandler restated an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, Barclays reduced their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the transaction, the executive vice president now directly owns 14,800 shares in the company, valued at approximately $2,237,316. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ZTS. Vanguard Group Inc. lifted its stake in shares of Zoetis by 1.0% during the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after buying an additional 414,605 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Zoetis by 31.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after purchasing an additional 3,244,074 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Zoetis by 2.5% in the third quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock valued at $2,147,730,000 after purchasing an additional 297,044 shares during the period. Capital World Investors increased its stake in Zoetis by 0.6% in the fourth quarter. Capital World Investors now owns 9,064,158 shares of the company’s stock valued at $1,788,988,000 after purchasing an additional 57,798 shares during the last quarter. Finally, Norges Bank purchased a new position in Zoetis during the fourth quarter worth about $980,646,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 0.5 %

Shares of Zoetis stock opened at $175.60 on Friday. Zoetis has a one year low of $144.80 and a one year high of $201.92. The company has a market cap of $80.13 billion, a P/E ratio of 33.83, a PEG ratio of 2.72 and a beta of 0.86. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The firm has a fifty day moving average of $170.23 and a two-hundred day moving average of $178.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. During the same period in the prior year, the company posted $1.31 earnings per share. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. On average, analysts forecast that Zoetis will post 5.76 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. The ex-dividend date is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.